Fulgent Reports First Quarter 2024 Financial Results
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Business Wire
Total Revenue of $64.5 millionCore Revenue grows 1% year-over-year to $63.2 millionReiterates Full Year 2024 Core Revenue Guidance of $280 million EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.First Quarter 2024 Results:Total Revenue of $64.5 millionCore Revenue1 grew 1% year-over-year to $63.2 millionGAAP loss of $13.5 million, or $0.45 per shareNon-GAAP loss of $269,000, or $0.01 per shareAdjusted EBITDA loss of $3.2 millionCash from operations of $7.3 millionCash, cash equivalents, and investments in marketable securities of $846.2 million as of March 31, 2024Note:1) Core Revenue is revenue calculated in accordance with GAAP minus revenue from COVID-19 testing products and services including COVID-19 NGS testing revenue, each as
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- Moffitt and Fulgent Pharma partner on personalised cancer therapies [Yahoo! Finance]Yahoo! Finance
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics [Yahoo! Finance]Yahoo! Finance
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsBusiness Wire
- Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain [Yahoo! Finance]Yahoo! Finance
- Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of PainPR Newswire
FLGT
Earnings
- 5/3/24 - Beat
FLGT
Sec Filings
- 5/16/24 - Form 8-K
- 5/7/24 - Form 4
- 5/7/24 - Form 4
- FLGT's page on the SEC website